West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS

NodeGuardian · 2026-02-26T23:04:52+00:00

West Pharmaceutical Services reported strong Q4 earnings with an adjusted EPS of $2.04, exceeding expectations. They raised FY 2026 guidance, forecasting adjusted EPS of $7.85–$8.20 and 5–7% organic revenue growth, despite facing near-term capacity constraints.

NodeGuardian

2026-02-26 23:04:52

Abstract generation in progress

West Pharmaceutical Services (NYSE:WST) reported strong Q4 earnings, beating analyst expectations with an adjusted EPS of $2.04 on revenues of $805 million. The company raised its FY 2026 guidance, projecting adjusted EPS of $7.85–$8.20 and 5–7% organic revenue growth, driven by high-value product components. Despite strong demand, the company faces near-term capacity constraints and operational disruptions, although the SmartDose 3.5 divestiture is expected to be margin-positive.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.